{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:58:14Z","timestamp":1777535894126,"version":"3.51.4"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The prognosis for infants less than 12 months of age who are diagnosed with acute lymphoblastic leukemia (ALL) remains poor despite overall advances in the treatment of childhood ALL. In this review, we highlight the recent advances in the understanding of the pathogenesis of infant ALL and discuss opportunities for translating these findings into clinical trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Infant ALL can be divided into two major disease types, defined by the presence or absence of <jats:italic toggle=\"yes\">KMT2A<\/jats:italic> (<jats:italic toggle=\"yes\">MLL<\/jats:italic>) rearrangement (KMT2A-R). Recent molecular profiling studies have found that infant ALL with KMT2A-R is an epigenomic disease that lacks other somatic driver mutations. Strategies to intensify therapy have not improved survival for infants with KMT2A-R ALL. In contrast, infant ALL without KMT2A-R is more similar to ALL of older children and survival has improved modestly with intensification of chemotherapy. Discovery of clonal molecular markers that predict chemoresistance will allow further risk classification and development of novel treatment strategies. Modern clinical trials are integrating molecularly targeted therapies into the treatment of infant ALL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Advances in molecular profiling and integration of targeted therapy have the potential to reduce toxicity and improve survival for infants with ALL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000437","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T12:00:12Z","timestamp":1478865612000},"page":"20-26","source":"Crossref","is-referenced-by-count":24,"title":["Updates in the biology and therapy for infant acute lymphoblastic leukemia"],"prefix":"10.1097","volume":"29","author":[{"given":"Erin M.","family":"Guest","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology\/Bone Marrow Transplantation, Children's Mercy Hospital and Clinics, Kansas City, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald W.","family":"Stam","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Paediatric Oncology, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/leu.2014.172","article-title":"Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia","volume":"29","author":"Koh","year":"2015","journal-title":"Leukemia"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2009.26.8938","article-title":"Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group","volume":"29","author":"Dreyer","year":"2011","journal-title":"J Clin Oncol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pbc.25322","article-title":"Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3)","volume":"62","author":"Dreyer","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1182\/blood-2005-11-4728","article-title":"Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group","volume":"107","author":"Nagayama","year":"2006","journal-title":"Blood"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/leu.2013.280","article-title":"Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements","volume":"28","author":"De Lorenzo","year":"2014","journal-title":"Leukemia"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.3324\/haematol.2014.122119","article-title":"Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities","volume":"101","author":"van der Linden","year":"2016","journal-title":"Haematologica"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1182\/blood-2009-02-204214","article-title":"Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol","volume":"114","author":"van der Linden","year":"2009","journal-title":"Blood"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V94.4.1209","article-title":"Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia","volume":"94","author":"D\u00f6rdelmann","year":"1999","journal-title":"Blood"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/leu.2009.17","article-title":"Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol","volume":"23","author":"Van der Velden","year":"2009","journal-title":"Leukemia"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/leu.2013.135","article-title":"The MLL recombinome of acute leukemias in 2013","volume":"27","author":"Meyer","year":"2013","journal-title":"Leukemia"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"13950","DOI":"10.1073\/pnas.94.25.13950","article-title":"Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots","volume":"94","author":"Gale","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2002-12-3817","article-title":"Leukemia in twins: lessons in natural history","volume":"102","author":"Greaves","year":"2003","journal-title":"Blood"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1073\/pnas.0503072102","article-title":"Global and Hox-specific roles for the MLL1 methyltransferase","volume":"102","author":"Guenther","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0037-1963(03)00196-3","article-title":"KMT2A-rearranged leukemias: insights from gene expression profiling","volume":"40","author":"Armstrong","year":"2003","journal-title":"Semin Hematol"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/ped.12758","article-title":"Recent progress in the treatment of infant acute lymphoblastic leukemia","volume":"57","author":"Tomizawa","year":"2015","journal-title":"Pediatr Int"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ccr.2009.12.040","article-title":"A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription","volume":"17","author":"Yokoyama","year":"2010","journal-title":"Cancer Cell"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1128\/MCB.00182-12","article-title":"The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output","volume":"32","author":"Luo","year":"2012","journal-title":"Mol Cell Biol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4161\/cc.27757","article-title":"MLL fusion-driven activation of CDK6 potentiates proliferation in KMT2A-rearranged infant ALL","volume":"13","author":"van der Linden","year":"2014","journal-title":"Cell Cycle"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2008.10.001","article-title":"H3K79 methylation profiles define murine and human MLL-AF4 leukemias","volume":"14","author":"Krivtsov","year":"2008","journal-title":"Cancer Cell"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/bjh.12250","article-title":"The distribution of MLL breakpoints correlates with outcome in infant acute leukaemia","volume":"161","author":"Emerenciano","year":"2013","journal-title":"Br J Haematol"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/leu.2014.154","article-title":"Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement","volume":"29","author":"Bardini","year":"2015","journal-title":"Leukemia"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2013.245","article-title":"Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in KMT2A-rearranged infant ALL","volume":"28","author":"Spijkers-Hagelstein","year":"2014","journal-title":"Leukemia"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2015.12.031","article-title":"Versican expression is an adverse prognostic factor in KMT2A-rearranged infant acute lymphoblastic leukaemia","volume":"57","author":"Driessen","year":"2016","journal-title":"Eur J Cancer"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2007-05-091934","article-title":"Prognostic significance of high-level FLT3 expression in KMT2A-rearranged infant acute lymphoblastic leukemia","volume":"110","author":"Stam","year":"2007","journal-title":"Blood"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1182\/blood-2011-10-382861","article-title":"Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"119","author":"Kang","year":"2012","journal-title":"Blood"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","article-title":"The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias","volume":"47","author":"Andersson","year":"2015","journal-title":"Nat Genet"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2407-13-55","article-title":"Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia","volume":"13","author":"Chang","year":"2013","journal-title":"BMC Cancer"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/gcc.22090","article-title":"The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia","volume":"52","author":"Dobbins","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/pbc.26100","article-title":"Relapsed infant KMT2A-rearranged acute lymphoblastic leukemia with additional genetic alterations","volume":"63","author":"Ishida","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2012.067983","article-title":"Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants","volume":"98","author":"Driessen","year":"2013","journal-title":"Haematologica"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/leu.2013.367","article-title":"Excess congenital non-synonymous variation in leukemia-associated genes in MLL-infant leukemia: a Children's Oncology Group report","volume":"28","author":"Valentine","year":"2014","journal-title":"Leukemia"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1182\/blood-2009-09-243634","article-title":"Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting","volume":"115","author":"Schafer","year":"2010","journal-title":"Blood"},{"key":"R34-20230918","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1182\/blood-2009-06-227660","article-title":"Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options","volume":"114","author":"Stumpel","year":"2009","journal-title":"Blood"},{"key":"R35-20230918","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2012.07.013","article-title":"Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemia-rearranged infant acute lymphoblastic leukaemia","volume":"49","author":"Stumpel","year":"2013","journal-title":"Eur J Cancer"},{"key":"R36-20230918","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/leu.2010.282","article-title":"Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale","volume":"25","author":"Stumpel","year":"2011","journal-title":"Leukemia"},{"key":"R37-20230918","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood.V126.23.809.809","article-title":"Identifying subclonal epigenetic changes driving chemoresistance in infant KMT2A-R acute lymphoblastic leukemias","volume":"126","author":"Kostadinov","year":"2015","journal-title":"Blood"},{"key":"R38-20230918","doi-asserted-by":"crossref","first-page":"e0120326","DOI":"10.1371\/journal.pone.0120326","article-title":"Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemia","volume":"10","author":"van der Linden","year":"2015","journal-title":"PLoS One"},{"key":"R39-20230918","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/pbc.24132","article-title":"Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407","volume":"59","author":"Salzer","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R40-20230918","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2004-06-2498","article-title":"FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression","volume":"105","author":"Brown","year":"2005","journal-title":"Blood"},{"key":"R41-20230918","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2004-09-3667","article-title":"Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia","volume":"106","author":"Stam","year":"2005","journal-title":"Blood"},{"key":"R42-20230918","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/pbc.25311","article-title":"Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group","volume":"62","author":"Salzer","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R43-20230918","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/sj.leu.2404903","article-title":"Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group","volume":"21","author":"Tomizawa","year":"2007","journal-title":"Leukemia"},{"key":"R44-20230918","first-page":"534","article-title":"Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies","volume":"91","author":"Biondi","year":"2006","journal-title":"Haematologica"},{"key":"R45-20230918","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2010-03-273532","article-title":"Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 study","volume":"116","author":"Mann","year":"2010","journal-title":"Blood"},{"key":"R46-20230918","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/pbc.26108","article-title":"Severe, persistent, and fatal T-cell immunodeficiency following therapy for infantile leukemia","volume":"63","author":"Geerlinks","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R47-20230918","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/pbc.21975","article-title":"Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: a report from the Japan Infant Leukemia Study Group","volume":"52","author":"Tomizawa","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R48-20230918","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/leu.2015.246","article-title":"Outcome of relapsed infant acute lymphoblastic leukemia treated on the Interfant-99 protocol","volume":"30","author":"Driessen","year":"2016","journal-title":"Leukemia"},{"key":"R49-20230918","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.ejca.2015.06.117","article-title":"The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia","volume":"51","author":"Stumpel","year":"2015","journal-title":"Eur J Cancer"},{"key":"R50-20230918","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.25953","article-title":"Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy","volume":"63","author":"Rayes","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R51-20230918","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood.V126.23.2046.2046","article-title":"First clinical application of Talen engineered universal CAR19 T cells in B-ALL","volume":"126","author":"Qasim","year":"2015","journal-title":"Blood"},{"key":"R52-20230918","article-title":"Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin","author":"Cruickshank","year":"2016","journal-title":"Leukemia"},{"key":"R53-20230918","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V126.23.3792.3792","article-title":"Preliminary report of the Phase I study of the DOT1L inhibitor, pinometostat, EPZ-5676, in children with relapsed or refractory MLL-r acute leukemia: safety, exposure, and target inhibition","volume":"126","author":"Shukla","year":"2015","journal-title":"Blood"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201702000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:05:57Z","timestamp":1695002757000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201702000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000437","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}